Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Indications and outcomes for sclera tunnel fixed secondary intraocular lenses: single centre series

Poster Details

First Author: F.Shams UK

Co Author(s):    Z. Koshy                    

Abstract Details

Purpose:

Insertion of sclera fixated posterior chamber intraocular lenses (PCIOL) allows lens implantation in the absence of adequate lens capsule support. We evaluate our experience with a 3 piece IOL fixed through scleral tunnels.

Setting:

Scleral fixed PCIOLs in a single surgeon series in a teaching hospital. University Hospital Ayr - NHS Ayrshire and Arran, Scotland

Methods:

Retrospective review of case notes of 13 eyes over a 2-year period (January 2013- February 2015).

Results:

Indications for secondary IOL insertion: 3 subluxed crystalline lenses from Marfans syndrome, 5 aphakia secondary to trauma both perforating and blunt, 1 dislocated crystalline lens, 1 aphakia secondary to complicated phacoemulsification surgery, 3 subluxed lens capsular bag complex. 38% of eyes had improved best-corrected visual acuity (BCVA) postoperatively, 30% remained the same and 20% worsened. 3 cases were found to have a mild postoperative PCIOL tilt, which had no visual implications. 2 developed postoperative retinal detachements (RD), which were subsequently fixed. 1 developed a suprachoroidal haemorrahge following post-operative trauma. 1 developed postoperative cystoid macula oedema that resolved with medical management.

Conclusions:

Our experience shows that insertion of scleral fixated PCIOLs is a viable method of secondary IOL insertion in multiple scenarios where lens capsular support is lacking. It is recommended that it be done with vitreoretinal back up due to potential complications.

Financial Disclosure:

NONE

Back to Poster listing